ReP USP - Resultado da busca

Artigo de periodico
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab (2018)
Ridker, Paul M.; Santos Filho, Raul Dias dos; Rose, Lynda M; Kastelein, John J. P; Wei, Caimiao; Revkin, James; YUNIS, Carla; Tardif, Jean-Claude; Shear, Charles L
Source: Journal of clinical lipidology. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES, HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS GENÉTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. Journal of clinical lipidology, v. 12, n. 4, p. 958-965, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2018.03.088. Acesso em: 01 nov. 2024.
APA
Ridker, P. M., Santos Filho, R. D. dos, Rose, L. M., Kastelein, J. J. P., Wei, C., Revkin, J., et al. (2018). Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. Journal of clinical lipidology, 12( 4), 958-965. doi:10.1016/j.jacl.2018.03.088
NLM
Ridker PM, Santos Filho RD dos, Rose LM, Kastelein JJP, Wei C, Revkin J, YUNIS C, Tardif J-C, Shear CL. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab [Internet]. Journal of clinical lipidology. 2018 ; 12( 4): 958-965.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.jacl.2018.03.088
Vancouver
Ridker PM, Santos Filho RD dos, Rose LM, Kastelein JJP, Wei C, Revkin J, YUNIS C, Tardif J-C, Shear CL. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab [Internet]. Journal of clinical lipidology. 2018 ; 12( 4): 958-965.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.jacl.2018.03.088
Artigo de periodico
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients (2017)
Ridker, Paul M.; Revkin, James; Amarenco, Pierre; Brunell, Robert; Curto, Madelyn; Civeira, Fernando; Flather, Marcus; Glynn, Robert J.; Gregoire, Jean; Jukema, J. Wouter; Karpov, Yuri; Kastelein, John J.P.; Koenig, Wolfgang; Lorenzatti, Alberto; Manga, Pravin; Masiukiewicz, Urszula; Miller, Michael; Mosterd, Arend; Murin, Jan; Nicolau, Jose C.; Nissen, Steven; Ponikowski, Piotr; Santos, Raul D.; Schwartz, Pamela F.; Soran, Handrean; White, Harvey; Wright, R. Scott; Vrablik, Michal; Yunis, Carla; Shear, Charles L.; Tardif, Jean-Claude
Source: The New England Journal of Medicine. Unidade: FM
Subjects: COLESTEROL, PLACEBO, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine, v. 376, n. 16, p. 1527-1539, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488. Acesso em: 01 nov. 2024.
APA
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., et al. (2017). Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine, 376( 16), 1527-1539. doi:10.1056/NEJMoa1701488
NLM
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1527-1539.[citado 2024 nov. 01 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488
Vancouver
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1527-1539.[citado 2024 nov. 01 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488
Artigo de periodico
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab (2017)
Ridker, Paul M.; Tardif, Jean-Claude; Amarenco, Pierre; Duggan, William; Glynn, Robert J.; Jukema, J. Wouter; Kastelein, John J.P.; Kim, Albert M.; Koenig, Wolfgang; Nissen, Steven; Revkin, James; Rose, Lynda M.; Santos, Raul D.; Schwartz, Pamela F.; Shear, Charles L.; Yunis, Carla
Source: The New England Journal of Medicine. Unidade: FM
Subjects: COLESTEROL, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, v. 376, n. 16, p. 1517-1526, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062. Acesso em: 01 nov. 2024.
APA
Ridker, P. M., Tardif, J. -C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., et al. (2017). Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, 376( 16), 1517-1526. doi:10.1056/NEJMoa1614062
NLM
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 nov. 01 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062
Vancouver
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 nov. 01 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em